Prostate. 1991;18(3):201-14.

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.

Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ.

Source

Department of Urology, Northwestern University Medical School, Chicago, IL.

Abstract

Plasminogen activators (PA), particularly the lower Mr urokinase (u-PA) type, have been associated with tumor cell invasion and metastasis. We have examined the expression of PA by two human prostate cancer cell lines (PC-3 and DU-145) using functional and immunologic techniques. The culture media and cell extracts of the more aggressive PC-3 cell line contained more than two-fold greater PA activity than the relatively indolent DU-145 cell line. Zymographic studies identified the PA expressed as u-PA. PC-3 cells expressed an additional lower molecular weight form of u-PA not noted in DU-145 cells. Heterogeneity in u-PA expression was shown by the fibrin lysis assay, immunohistochemistry, and dual parameter flow cytometry indicating the presence of phenotypically divergent cell populations. Increased u-PA expression may identify those tumor cells that possess aggressive biological potential.

PMID:: 1902292; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

P50-DK39250/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Supplemental Content

Save items

Related citations in PubMed

Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells. [Clin Cancer Res. 1995]
Retinoic acid modulates extracellular urokinase-type plasminogen activator activity in DU-145 human prostatic carcinoma cells.
Waghray A, Webber MM. Clin Cancer Res. 1995 Jul; 1(7):747-53.
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype. [J Urol. 1989]
Plasminogen activators in human prostate cancer cell lines and tumors: correlation with the aggressive phenotype.
Gaylis FD, Keer HN, Wilson MJ, Kwaan HC, Sinha AA, Kozlowski JM. J Urol. 1989 Jul; 142(1):193-8.
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. [Prostate. 1995]
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines.
Lyon PB, See WA, Xu Y, Cohen MB. Prostate. 1995 Oct; 27(4):179-86.
Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo. [Prostate. 1997]
Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
Quax PH, de Bart AC, Schalken JA, Verheijen JH. Prostate. 1997 Aug 1; 32(3):196-204.
Review The urokinase-type plasminogen activator system in cancer metastasis: a review. [Int J Cancer. 1997]
Review The urokinase-type plasminogen activator system in cancer metastasis: a review.
Andreasen PA, Kjøller L, Christensen L, Duffy MJ. Int J Cancer. 1997 Jul 3; 72(1):1-22.

See reviews... See all...

Cited by 5 PubMed Central articles

Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro. [BMC Complement Altern Med. 2010]
Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro.
Yaacob NS, Hamzah N, Nik Mohamed Kamal NN, Zainal Abidin SA, Lai CS, Navaratnam V, Norazmi MN. BMC Complement Altern Med. 2010 Aug 5; 10:42. Epub 2010 Aug 5.
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. [Cancer Res. 2007]
Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer.
Pulukuri SM, Estes N, Patel J, Rao JS. Cancer Res. 2007 Feb 1; 67(3):930-9.
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. [Mol Cell Biol. 2006]
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Annicotte JS, Iankova I, Miard S, Fritz V, Sarruf D, Abella A, Berthe ML, Noël D, Pillon A, Iborra F, et al. Mol Cell Biol. 2006 Oct; 26(20):7561-74.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell...
Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.
Prostate. 1991 ;18(3):201-14.

PubMed
Empowering women to obtain high quality care: evidence from an evaluation of Mex...
Empowering women to obtain high quality care: evidence from an evaluation of Mexico's conditional cash transfer programme.
Health Policy Plan. 2009 Jan ;24(1):18-25. Epub 2008 Nov 20 .

PubMed
Stabilization of clathrin coated vesicles by amantadine, tromantadine and other ...
Stabilization of clathrin coated vesicles by amantadine, tromantadine and other hydrophobic amines.
FEBS Lett. 1991 Apr 9 ;281(1-2):188-90.

PubMed
Cardiovascular risk in South Asians.
Cardiovascular risk in South Asians.
Postgrad Med J. 2008 Oct ;84(996):518-23.

PubMed
Is the end-tidal partial pressure of isoflurane a good predictor of its arterial...
Is the end-tidal partial pressure of isoflurane a good predictor of its arterial partial pressure?
Br J Anaesth. 1991 Mar ;66(3):331-9.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: increased PA activity correlates with biologically aggressive behavior.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Other Literature Sources

Medical

Libraries

Supplemental Content

Save items

Related citations in PubMed

Cited by 5 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information